In today’s recent session, 19.24 million shares of the NLS Pharmaceutics Ltd (NASDAQ:NLSP) have been traded, and its beta is -0.43. Most recently the company’s share price was $2.49, and it changed around $0.67 or 37.09% from the last close, which brings the market valuation of the company to $6.04M. NLSP at last check was trading at a discount to its 52-week high of $24.34, offering almost -877.51% off that amount. The share price’s 52-week low was $1.73, which indicates that the recent value has risen by an impressive 30.52% since then. We note from NLS Pharmaceutics Ltd’s average daily trading volume that its 10-day average is 0.24 million shares, with the 3-month average coming to 380.11K.

NLS Pharmaceutics Ltd stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended NLSP as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. NLS Pharmaceutics Ltd is expected to report earnings per share of 0 for the current quarter.

NLS Pharmaceutics Ltd (NASDAQ:NLSP) trade information

Instantly NLSP has been showing a green trend so far today with a performance of 37.09% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.9500 on recent trading dayincreased the stock’s daily price by 15.59%. The company’s shares are currently down -89.43% year-to-date, but still up 27.95% over the last five days. On the other hand, NLS Pharmaceutics Ltd (NASDAQ:NLSP) is -23.70% down in the 30-day period. We can see from the shorts that 0.13 million shares have been sold at a short interest cover period of 0.33 day(s).

NLS Pharmaceutics Ltd (NASDAQ:NLSP)’s Major holders

ARMISTICE CAPITAL, LLC, with 6.0535% or 2.31 million shares worth $0.5 million as of 2024-06-30, holds the second largest percentage of outstanding shares.